Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xingya Li

Showing results (101-110 of 146) with videos related to

Pageof 15
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 17, 2024
Safety, Efficacy, and Biomarker Analysis of Deulorlatinib (TGRX-326) in Anaplastic Lymphoma Kinase-Positive NSCLC: A Multicenter, Open-Label, Phase 1/1b TrialShen Zhao, Huaqiang Zhou, Nong Yang, et al.
Signal Transduction and Targeted Therapy|January 12, 2025
A multicenter, randomized, double-blind, placebo-controlled phase 3 study of Socazolimab or placebo combined with carboplatin and etoposide in the first-line treatment of extensive-stage small cell lung cancerZhiwei Chen, Jianhua Chen, Dingzhi Huang, et al.
Nature Medicine|April 10, 2025
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trialsShen Zhao, Ying Cheng, Qiming Wang, et al.
European Journal of Cancer (Oxford, England : 1990)|April 30, 2025
Surufatinib in advanced neuroendocrine tumours: Final overall survival from two randomised, double-blind, placebo-controlled phase 3 studies (SANET-ep and SANET-p)Jianming Xu, Lin Shen, Jie Li, et al.
Therapeutic Advances in Medical Oncology|August 2, 2024
A pooled analysis of clinical outcome in driver-gene negative non-small cell lung cancer patients with MET overexpression treated with gumarontinibYongfeng Yu, Wen Dong, Yanxia Shi, et al.
Therapeutic Advances in Medical Oncology|November 7, 2022
Circulating tumour DNA biomarkers in savolitinib-treated patients with non-small cell lung cancer harbouring <i>MET</i> exon 14 skipping alterations: a <i>post hoc</i> analysis of a pivotal phase 2 studyYongfeng Yu, Yongxin Ren, Jian Fang, et al.
Lancet (London, England)|January 16, 2026
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trialShun Lu, Jie Wang, Nong Yang, et al.
Cancer Cell|October 24, 2025
TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 studyJia Zhong, Lin Wu, Zhengbo Song, et al.
The Lancet. Respiratory Medicine|July 19, 2021
Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trialJianxing He, Chunxia Su, Wenhua Liang, et al.
Translational Lung Cancer Research|October 24, 2025
Long-term follow-up results from the GLORY study: phase II study of gumarontinib in East Asian patients with <i>MET</i> exon 14 skipping mutated non-small cell lung cancerShun Lu, Yongfeng Yu, Jianya Zhou, et al.
Pageof 15

Showing results (101-110 of 146) with videos related to

Sort By:
Pageof 15
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 17, 2024
Safety, Efficacy, and Biomarker Analysis of Deulorlatinib (TGRX-326) in Anaplastic Lymphoma Kinase-Positive NSCLC: A Multicenter, Open-Label, Phase 1/1b TrialShen Zhao, Huaqiang Zhou, Nong Yang, et al.
Signal Transduction and Targeted Therapy|January 12, 2025
A multicenter, randomized, double-blind, placebo-controlled phase 3 study of Socazolimab or placebo combined with carboplatin and etoposide in the first-line treatment of extensive-stage small cell lung cancerZhiwei Chen, Jianhua Chen, Dingzhi Huang, et al.
Nature Medicine|April 10, 2025
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trialsShen Zhao, Ying Cheng, Qiming Wang, et al.
European Journal of Cancer (Oxford, England : 1990)|April 30, 2025
Surufatinib in advanced neuroendocrine tumours: Final overall survival from two randomised, double-blind, placebo-controlled phase 3 studies (SANET-ep and SANET-p)Jianming Xu, Lin Shen, Jie Li, et al.
Therapeutic Advances in Medical Oncology|August 2, 2024
A pooled analysis of clinical outcome in driver-gene negative non-small cell lung cancer patients with MET overexpression treated with gumarontinibYongfeng Yu, Wen Dong, Yanxia Shi, et al.
Therapeutic Advances in Medical Oncology|November 7, 2022
Circulating tumour DNA biomarkers in savolitinib-treated patients with non-small cell lung cancer harbouring <i>MET</i> exon 14 skipping alterations: a <i>post hoc</i> analysis of a pivotal phase 2 studyYongfeng Yu, Yongxin Ren, Jian Fang, et al.
Lancet (London, England)|January 16, 2026
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trialShun Lu, Jie Wang, Nong Yang, et al.
Cancer Cell|October 24, 2025
TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 studyJia Zhong, Lin Wu, Zhengbo Song, et al.
The Lancet. Respiratory Medicine|July 19, 2021
Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trialJianxing He, Chunxia Su, Wenhua Liang, et al.
Translational Lung Cancer Research|October 24, 2025
Long-term follow-up results from the GLORY study: phase II study of gumarontinib in East Asian patients with <i>MET</i> exon 14 skipping mutated non-small cell lung cancerShun Lu, Yongfeng Yu, Jianya Zhou, et al.
Pageof 15